Kidney Cancer Drugs Market Set to Witness Growth Owing to Increasing Prevalence of Cancer
![]() |
Kidney Cancer Drugs Market |
Kidney
cancer drugs are used for the treatment of one of the most common types of
cancer, kidney cancer. These drugs function by slowing or stopping the growth
of cancer cells or killing the cancer cells. Kidney cancer drugs include
angiogenesis inhibitors, mTOR inhibitors, and vaccines. Angiogenesis inhibitors
work by preventing the growth of new blood vessels that tumors need to grow.
mTOR inhibitors slow tumor cell growth by blocking a specific protein called
mTOR that helps tumor cells grow. Vaccines train the immune system to recognize
and attack cancer cells.
The Global
Kidney Cancer Drugs Market Demand is estimated to be valued at US$ 7.15
Bn in 2024 and is expected to exhibit a CAGR of 9.7% over the forecast period
2024 to 2030.
Rising prevalence of kidney cancer around the world is the prime factor driving
the growth of the kidney cancer drugs market. According to the American Cancer
Society, kidney cancer is among the ten most common cancers in both men and
women. Other factors fueling the demand for kidney cancer drugs include growing
geriatric population, increasing adoption of targeted drug therapies, and
approval and launch of novel drugs. However, high treatment costs and adverse
effects associated with drug therapies may hamper the market growth.
Key Takeaways
Key players operating in the kidney cancer drugs market are Celanese
Corporation, British Petroleum, Eastman Chemical Company, Jiangsu Sopo (Group)
Co., Ltd., China Petroleum & Chemical Corporation (Sinopec), Lyondell
Basell Industries, Saudi Basic Industries Corporation (SABIC), Mitsubishi
Chemical Company, PetroChina Co. Ltd., PetroChina Co. Ltd., BASF SE. These
players are focusing on developing new targeted drugs through research and
developmental activities.
The global kidney cancer drugs market presents lucrative growth opportunities
owing to rising investments in R&D of novel targeted drug therapies.
Further, growing kidney cancer burden in developing countries offers
opportunities for market players to expand their geographic footprint.
The key market players are engaging in mergers and acquisitions and
partnerships to strengthen their product portfolio and global presence. For
instance, in 2021, Eisai and Merck gained FDA approval for Lenvima (lenvatinib)
for the treatment of advanced renal cell carcinoma in combination with
pembrolizumab.
Market Drivers
Growing prevalence of kidney cancer worldwide is a major factor driving the
demand for kidney cancer drugs. Rising geriatric population is also
contributing to the market growth as kidney cancer is more common in older
adults. Further, increasing R&D investments by key players for development
of novel targeted therapies is anticipated to propel the kidney cancer drugs
market over the forecast period.
Market Restraints
High treatment costs associated with kidney cancer drugs poses significant challenges
for widespread adoption. Adverse effects of drug therapies also limit their
uptake. Further, lack of awareness about kidney cancer in developing nations
also hampers the market growth. Stringent regulatory framework for approval of
new drugs also acts as a restraint.
Segment Analysis
The kidney cancer drugs market is segmented based on diagnostic techniques,
therapy type and end users. Chemotherapy held dominating share due to the
strong demand for drugs such as Sunitinib and Pazopanib. These drugs inhibit
specific tyrosine kinases, thereby halting cancer progression. Their effective
results in slowing tumor growth drive segment sales.
Immunotherapy sub segment is witnessing highest growth on account of
introduction of inhibitors targeting specific immune pathways. Drugs like
Nivolumab and Pembrolizumab help strengthen the body’s natural defenses to
fight cancer. Their ability to stimulate the immune system for sustainable
response against tumor cells boosts segment revenue.
Global Analysis
North America accounted for the largest share in the kidney cancer drugs market
in 2024 owing to rising incidence of renal cell carcinoma and presence of
developed healthcare infrastructure and reimbursement policies. Asia Pacific is
anticipated to grow at a notable pace during the forecast period. Increasing
healthcare spending, expanding private sector, and widening patient pool drive
regional market growth. Key players focus on tapping opportunities in emerging
economies like India and China to strengthen their geographic footprint.
For more insights, Read- https://www.marketwebjournal.com/kidney-cancer-drugs-market-trends-size-and-share-analysis/
Comments
Post a Comment